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Abstract
Long-term outcome – mortality, morbidity and quality of life – is
finally receiving attention in the field of intensive care research. A
number of recent studies have focused on patient survival and
kidney survival after acute renal failure. The present review focuses
on the third publication from the Beginning and Ending Supportive
Therapy for the Kidney Investigators Writing Committee. Their
study took place in 54 intensive care units in 23 countries. The
main findings of the Beginning and Ending Supportive Therapy
study was that the choice of continuous renal replacement therapy
as the initial therapy is not a predictor of hospital survival or of
dialysis-free hospital survival, but that it is an independent predictor
of renal recovery among survivors. In conclusion, the critical care
research community needs to focus on long-term outcome. A
number of recent studies of acute renal failure have done just that.
The issues of long-term outcome – mortality, morbidity and
quality of life – are finally receiving attention in the field of
intensive care research. This attention is paramount for the
critical care community. We need to look above and beyond
simple intensive care unit mortality. We owe it to our patients
and to their relatives to learn as much as we can about what
we as clinicians can do to improve long-term outcome.
A recent study focused on an initial technique of renal
replacement therapy and its effect on patient survival and
kidney survival in critically ill patients with acute kidney injury
[1]. The study is the third publication from the Beginning and
Ending Supportive Therapy for the Kidney Investigators
Writing Committee. Enrolling 1,218 patients treated with
continuous renal replacement therapy (CRRT) or with inter-
mittent renal replacement therapy (IRRT) for acute renal
failure in 54 intensive care units in 23 countries, the investiga-
tors followed the patients to death or to hospital discharge.
Their findings were interesting; patients treated with CRRT
(n = 1,006, 82.6%) had higher illness severity scores and
required vasopressor drugs and mechanical ventilation more
frequently compared with those receiving IRRT (n = 212,
17.4%). The reasons for initiating renal replacement therapy
also differed; for instance, sepsis was more common in the
CRRT group. Considering the different patient categories,
the authors unsurprisingly found that unadjusted hospital
survival was lower in the CRRT group. Multivariable logistic
regression, however, showed that the choice of renal
replacement therapy was not an independent predictor of
hospital survival or of dialysis-free hospital survival. Most
importantly, the study showed that the choice of CRRT was a
predictor of dialysis independence at hospital discharge
among survivors (odds ratio = 3.3, 95% confidence interval =
1.8–6.0, P < 0.0001). The authors conclude that, worldwide,
the choice of CRRT as the initial therapy is not a predictor of
hospital survival or of dialysis-free hospital survival, but that it
is an independent predictor of renal recovery among
survivors. The authors speculate on the reasons for this, and
on whether hypotension plays a part. The numbers of
reported hypotensive episodes were indeed significantly
higher in the IRRT group than in the CRRT group (27.9% and
18.8%, respectively).
Perhaps it is the poor outcome [2] – measured as mortality –
of critically ill patients with acute renal failure that has
prevented the research community from evaluating the
determinants of long-term morbidity. The vast differences
between countries and regions concerning the choice of the
initial technique of renal replacement therapy could also
have hampered this field of research [3-5]. Surgery and
internal medicine are disciplines with several hundred years
of history – is this an explanation for the fact that long-term
outcome is an integrated and natural part of clinical studies
in those fields?
The adolescent specialty of intensive care medicine, born in
1952 after the polio epidemic in Copenhagen [6], has been
satisfied with less; namely, with the reporting of short-term
mortality.
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CRRT = continuous renal replacement therapy; IRRT = intermittent renal replacement therapy.Page 2 of 3
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Renal recovery is an important measure of outcome for many
reasons. First, chronic dialysis therapy is associated with
significant impairment of health-related quality of life [7-9].
Dialysis therapy is also costly, with annual costs in the range
of $51,252–69,517 [10,11]. One study showed that the
estimated cost per quality-adjusted life-year saved by initiating
dialysis was $128,200 [12]. Finally, the overall mortality of
patients with renal failure requiring dialysis exceeds that of the
general population. Recent Swedish data from the Swedish
Register of Active Uremia report a 28.1% yearly mortality ratio
for patients on chronic hemodialysis [13].
In collaboration with the Swedish Intensive Care Nephrology
Group, we performed a study of 2,202 patients with acute
renal failure [14]. These patients were treated with either
CRRT or IRRT in 32 Swedish intensive care units. The
duration of follow-up ranged from 3 months to 10 years.
We addressed the same issue as the Beginning and Ending
Supportive Therapy investigators [1]; namely whether treatment
modality used during intensive care affects renal recovery. A
total of 1,100 patients died within 90 days of initial dialysis.
No association was found between dialysis modality and 90-
day mortality. Among the 90-day survivors, 944 had received
CRRT and 158 had received IRRT. The risk of end-stage
renal disease requiring hemodialysis was considerably higher
in 90-day survivors treated with IRRT than in those treated
with CRRT (adjusted odds ratio = 2.60, 95% confidence
interval = 1.5–4.3). The trend towards a higher risk of end-
stage renal disease with IRRT, however, decreased with
increasing duration of follow-up. Among the 90-day survivors
who did develop end-stage renal disease, the risk of death
was markedly higher in patients treated with IRRT than in
those treated with CRRT (hazard ratio = 2.3, 95% confi-
dence interval = 1.3–4.1).
In conclusion, the Beginning and Ending Supportive Therapy
study shows that CRRT and IRRT are used for quite different
patient categories, where sicker and more hemodynamically
unstable patients more often than not are treated with CRRT.
Furthermore, both that study and the national study by the
Swedish Intensive Care Nephrology Group investigators
point to the fact that CRRT is associated with a bigger
chance of renal recovery.
The findings of these two large studies (1,218 and 2,202
patients, respectively) are in keeping with previous clinical
evidence. In a randomized controlled trial by Mehta and
colleagues, benefits for CRRT regarding renal recovery were
seen [15]. Chronic renal insufficiency at death or at hospital
discharge was diagnosed in 17% of patients with initial
therapy of IRRT versus only 4% of patients whose initial
therapy was CRRT (P = 0.01). For patients receiving an
adequate trial of monotherapy, the recovery of renal function
was 92% for CRRT versus 59% for IRRT (P < 0.01). Finally,
a higher percentage of subjects crossing over from IRRT to
CRRT recovered their renal function compared with the
patients crossing over in the opposite direction (45% versus
7%, respectively; P < 0.01) [15]. As higher costs associated
with CRRT have been used in the debate regarding the
choice of modality, the downstream costs of end-stage renal
disease requiring chronic hemodialysis may have to be
considered in future discussions. Naturally, we do look
forward to long-term studies of renal outcome on patients
treated with sustained low efficiency (daily) dialysis.
As members of the intensive care research community, we
need to strive towards gathering more data concerning long-
term outcome. The studies mentioned above are welcome
additions to critical care epidemiology in general, and to the
field of acute kidney injury in particular.
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